Loading company
Palisade BIO, Inc.
PALI · Nasdaq · ·
Next earnings: November 9, 2026
$1.45-3.7%Sep 29 close
- 1M
- -27.7%
- 6M
- -18.8%
- 1Y
- +68.1%
- 5Y
- -99.9%
Palisade BIO, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $500K | $0.00 | — |
| Profit | -$10.6M | -$2.8M | -279.81% |
| Profit per share | -$0.05 | -$0.58 | +91.38% |
| Free Cash Flow | -$2.4M | -$3.3M | +28.20% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter marked a decisive transition for Palisade Bio as we completed the regulatory and operational work required to advance PALI-2108 into Phase 2 development,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases. The Company’s lead clinical product candidate, PALI-2108, is being advanced into Phase 2 clinical trials as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Despite the availability of multiple biologic and small-molecule therapies, many patients with UC and CD do not achieve durable remission, lose response over time, or discontinue treatment because of safety or tolerability limitations. The Company believes PALI-2108 has the potential to address these limitations through once-daily oral dosing, targeted lower-intestinal bioactivation and broad PDE4-mediated anti-inflammatory activity. Palisade Bio is now advancing into Phase 2 development for UC and CD.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Palisade BIO, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Palisade BIO, Inc. has no earnings call transcript available.
PALI · Nasdaq · ·
Next earnings: November 9, 2026
$1.45-3.7%Sep 29 close